Transparent Disclosure of AD Biomarker Results to Patients and Caregivers
Jennifer H. Lingler, PhD, CRNP, FAAN, a Professor of Nursing and Psychiatry at the University of Pittsburgh spoke at the 2023 IOA Retreat to discuss how practitioners can be responsibly transparent towards patients and their caregivers regarding Alzheimer’s Disease (AD) biomarker results.
Dr. Lingler is motivated to effectively communicate AD biomarker results in a way that is not only transparent, but also clear and easy to understand. Dr. Lingler experienced firsthand the impact of ineffective communication of patient results on the caregiver and patient as a bystander. During her talk, Dr. Lingler reminisced on a personal experience in which she…
View Full Post
The Science of Aging: An IOA Newsletter, Spring 2024 Edition | DIGITAL VERSION
When conducting a clinical trial, investigators have ethical obligations throughout the entire course of the study, including the post-trial period. Some obligations may be more obvious during the pre-trial and trial periods, but the post-trial period is more of a “black box†with unseen inner workings, explained Emily Largent, PhD, RN, Emanuel and Robert Hart Assistant Professor of Medical Ethics & Health Policy at Penn Medicine, during a presentation at the IOA's 
Virginia Lee, PhD, and the late John Q. Trojanowski, MD, PhD, partners in life and in science, have long been recognized as trailblazers in the field of neurodegenerative disease research. Now, their legacy will be immortalized in the halls of the University of Pennsylvania, as they join the list of leaders at Penn who have been celebrated with portraits to honor their impacts and contributions not only to the university, but to their respective fields.